Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
NCT05041140
Recruiting
This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD). The primary objective of the study is to correlate 129-Xenon measures of ventila... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pulmonary, Pneumonia, Hematopoietic System--Cancer
Register for Updates
Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents.
NCT06990724
Recruiting
The purpose of this study is to evaluate the effectiveness of a videogame compared to an attention/time control at reducing contraceptive non-use among adolescents.
Gender:
ALL
Ages:
Between 15 years and 20 years
Trial Updated:
08/08/2025
Locations: Bronx Health Link, Bronx, New York +5 locations
Conditions: Contraceptive Usage, Contraception Behavior
Register for Updates
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909
Recruiting
This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone. This study has a crossover period, where subjects on st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Site 17, Guntersville, Alabama +20 locations
Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Register for Updates
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854
Recruiting
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Retinal Consultants of AZ, Ltd, Peoria, Arizona +25 locations
Conditions: Diabetic Macular Edema
Register for Updates
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
NCT06106360
Recruiting
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Solid Tumor, Hematological Malignancy
Register for Updates
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371
Recruiting
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
08/08/2025
Locations: Eastern Shore Research Institute, LLC, Fairhope, Alabama +12 locations
Conditions: Symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF)
Register for Updates
Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg
NCT06260956
Recruiting
Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/08/2025
Locations: University of Rochester, Rochester, New York
Conditions: Allergy and Immunology, Peanut and Nut Allergy, Egg Allergy, Food Allergy in Infants, Food Allergy Peanut
Register for Updates
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786
Recruiting
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidom... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/08/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado +2 locations
Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Register for Updates
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
NCT06962904
Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/08/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
Register for Updates
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325
Recruiting
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/08/2025
Locations: Catalina Eye Care, Tuscon, Arizona +46 locations
Conditions: Thyroid Eye Disease (TED)
Register for Updates
Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
NCT06864338
Recruiting
The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Virtual Research Group, Morrisville, North Carolina
Conditions: Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
Register for Updates
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
NCT06086275
Recruiting
This is a human laboratory-based, randomized, cross-over study in which buprenorphine will be administered to healthy volunteers (n=22) in 3 separate inpatient 2-night visits, at least 1 week apart. At each visit, the participant will receive a single dose buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO. Participants will be given naltrexo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Brigham and Women's hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder
Register for Updates